Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Q1 2014 Earnings Presentation
26 slides from Cytosorbents's earnings presentation, May 19, 2014
Slide 1: An Emerging Leader in Critical Care Immunotherapy: Q1 2014 Review
Cyto Sorbents Corporation OTCBB: CTSO An Emerging Leader in Critical Care Immunotherapy Q1 2014 Review – May 14, 2014
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are not historical facts are forward - looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ
Slide 3: Conference Call Participants
3 Conference Call Participants Dr . Phillip Chan, MD, PhD Chief Executive Officer and President Vincent Capponi , MS Chief Operating Officer Kathleen Bloch, MBA, CPA Chief Financial Officer Dr . Christian Steiner, MD Vice President of Sales and Marketing Christopher Cramer, MS, MBA Vice President of
Slide 4: Emerging Leader in the $20B Critical Care Immunotherapy Space
4 Cyto Sorbents is an Emerging Leader in the $20B Critical Care Immunotherapy Space Leading the Prevention or Treatment of Life - Threatening Inflammation in the ICU
Slide 5: CytoSorb Removes the Fuel to the Fire
5 Cyto Sorb ® Removes the Fuel to the Fire • CytoSorb ® represents a powerful immunotherapy to control inflammation • Approved in the European Union as the only specifically approved extracorporeal cytokine filter • Clinically proven to reduce key cytokines in blood by 30 - 50% in critically ill pat
Slide 6: The Heart of the Technology
6 The Heart of the Technology The underlying blood purification technology is based on state - of - the - art biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood • Protected by 32 issued US patents and multiple applications pending • Manufact
Slide 7: Goal: To Prevent or Treat Organ Failure
7 Goal: To Prevent or Treat Organ Failure Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine Improve Patient Outcome and Survival Decrease Costs Of ICU and Patient Care
Slide 8: Q1 2014 Operating and Financial Highlights
8 Q1 2014 Operating and Financial Highlights
Slide 9: CytoSorb: An Excellent Business Model
9 • Huge market CytoSorb ® is sold to hospitals and critical care physicians, targeting a “need to have” $ 20 billion worldwide critical care opportunity addressing organ failure • Little to no competition • Critical care physicians understand the problem • It is a plug and play high margin disposab
Slide 10: Raised $10.2M in March 2014
10 Raised $10.2M in March 2014 • Fortified balance sheet with net proceeds of $9.5M cash from our financing • Enables aggressive growth strategy, focused on growing CytoSorb® sales, generating clinical data, and product development • Currently have estimated 1 - 2 years of cash to be supplemented wi
Slide 11: Middle East Expansion with Techno Orbits
11 Middle East Expansion with Techno Orbits • Exclusive distribution agreement • Includes the Gulf Cooperation Council (GCC) countries of Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, and Bahrain and related states of Yemen, Iraq, and Jordan • 105 million people in this territory • Many t
Slide 12: E.U. Approval Opens Global Distribution
12 E.U. Approval Opens Global Distribution Signed 18 countries including the UK, Ireland, Netherlands, Turkey, Russia, India and Middle East covering ~1.7 billion lives. Expanding to other parts of Europe and other countries outside the EU that accept the CE Mark WMC Intensiv Med LLC
Slide 13: Q1 2014 Revenue Results
13 Q1 2014 Revenue Results • Q1 2014 total revenue was ~$1.1M, compared to total Q1 2013 revenues of $371,000 • CytoSorb ® Q1 2014 product sales were ~$569,000, an increase of 223% over Q1 2013 product sales of ~$176,000 • Grant income for Q1 2014 was ~$491,000, compared to grant income of ~$195,000
Slide 14: Continuing Strong Product Growth
14 Continuing Strong Product Growth $13,679 $87,960 $176,098 $127,969 $203,561 $314,159 $569,243 $0 $100,000 $200,000 $300,000 $400,000 $500,000 $600,000 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 CytoSorb ® Product Sales 14 Q1 2014 Product Sales increased 81% from the prior quarter.
Slide 15: Product Sales (TTM)
15 Product Sales (TTM) $151,574 $310,779 $405,706 $595,588 $821,787 $1,214,932 $- $200,000 $400,000 $600,000 $800,000 $1,000,000 $1,200,000 $1,400,000 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Trailing Twelve Month Product Sales Trend Line
Slide 16: Working Capital: Capital Available to Fund Growth
16 Working Capital Capital Available to Fund Growth • Receipt of net proceeds of $9,451,000 from our March 11, 2014 preregistered offering has strengthened our balance sheet. • Receipt of approximately $458,000 from sale of our operating losses under the New Jersey Technology Business Tax Certificat
Slide 17: Rationale for Using CytoSorb for Existing and Emerging Viral Threats
17 Rationale for Using CytoSorb ® for Existing and Emerging Viral Threats
Slide 18: The Influenza Emergency
18 The Influenza Emergency Seasonal influenza afflicts 60+ million Americans each year, hospitalizing 200,000 and killing 36,000 despite broad availability of vaccines and anti - virals * • Swine flu (2009 H1N1) pandemic lessons • We cannot rely on vaccination alone. 30 - 70M Americans contracted H1
Slide 19: The Other Important Lesson Learned
19 The Other Important Lesson Learned Influenza patients often die when they develop “cytokine storm”and multiple - organ failure • Seasonal flu only affects the lungs, y et patients routinely die of multiple organ failure and secondary bacterial sepsis • Cytokines are an essential part of the anti
Slide 20: Influenza Case Report
20 Influenza Case Report Treatment day 1 2 3 4 5 6 7 IL - 6 (before) pg/mL 8,076 1,025 527 172 117 120 107 IL - 6 (after) pg/mL 2,621 663 289 76 110 111 94 IL - 6 (% change) - 68% - 35% - 45% - 56% - 6% - 8% - 12% - 2 - 1 0 1 3 2 4 5 6 7 8 10 11 9 ICU Admit Start CytoSorb CytoSorb Treatment Weaned o
Slide 21: Lessons Learned from SARS
21 Lessons Learned from SARS • 2002 - 2003 Pandemic: 8,098 infected, 774 people died (~10 % mortality)* • Patients died due to pulmonary complications such as ARDS (particularly in age > 60 ), multiple organ failure, secondary bacterial pneumonias, and had other complications such as diarrhea and ly
Slide 22: MERS Coronavirus
22 MERS Coronavirus • The mechanism of injury is likely the same as SARS and influenza, though mortality appears significantly higher • Based on WHO reports, there have been 538 documented cases of MERS in 17 countries, with 174 deaths (~25% mortality) with an increasing number of cases since March
Slide 23: Recent Visit to Saudi Arabia
23 Recent Visit to Saudi Arabia Prince Mohammed Bin Abdulaziz Hospital in Riyadh, Saudi Arabia
Slide 24: Where We Stand with MERS
24 Where We Stand with MERS • We have used CytoSorb® successfully in several patients with viral sepsis and multi - organ failure due to influenza, where a reduction in cytokines coincided with clinical improvement • Similarly, there is good scientific rationale to why CytoSorb® could be helpful in
Slide 25: CytoSorbents is Leading the Way to Prevent or Treat Life Threatening Inflammation
25 Cyto Sorbents is Leading the Way To Prevent or Treat Life Threatening Inflammation • CytoSorb ® targets deadly inflammation in the ICU that leads to organ failure and death • It is approved in the E.U. a nd is generating international revenue • Untapped $20B market opportunity and crucial unmet m
Slide 26: Contact and Q&A Session
26 Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 pchan@cytosorbents.com Cyto Sorbents Corporation OTCBB: CTSO The Rise of An Emerging Critical Care Immunotherapy Company Q&A Session